-
公开(公告)号：US20190218279A1
公开(公告)日：2019-07-18
申请号：US16246326
申请日：2019-01-11
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US20180079790A1
公开(公告)日：2018-03-22
申请号：US15826442
申请日：2017-11-29
Applicant: Amgen Inc.
Inventor： Yumei XIONG , Yi ZHANG , Jackie Z. SHENG , Agnes Eva HAMBURGER , Murielle M. VENIANT-ELLISON , Grant SHIMAMOTO , Xiaoshan MIN , Zhulun WANG , Jie TANG , Gunasekaran KANNAN , Marissa MOCK , Kenneth William WALKER
IPC: C07K14/475
CPC classification number: C07K14/475 , C07K2319/30
Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
公开(公告)号：US20150010560A1
公开(公告)日：2015-01-08
申请号：US14304559
申请日：2014-06-13
Applicant: Amgen Inc.
Inventor： Cen XU , Agnes Eva HAMBURGER
IPC: C07K16/28
CPC classification number: C07K16/28 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
Abstract translation: 提供了结合人PAC1的抗体及其抗原结合片段。 还提供了编码抗体及其抗原结合片段，载体和编码其的细胞的核酸。 抗体及其抗原结合片段可以抑制PAC1与PACAP的结合，并且可用于许多PAC1相关疾病，包括治疗和/或预防头痛障碍，包括偏头痛。
-
Patent Agency Ranking
公开(公告)号：US20240150448A1
公开(公告)日：2024-05-09
申请号：US18545688
申请日：2023-12-19
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
CPC classification number: C07K16/18 , A61K38/2278 , A61P25/06 , C07K16/2869 , A61K2039/545 , C07K2317/34 , C07K2317/565 , C07K2317/92
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US20220363770A1
公开(公告)日：2022-11-17
申请号：US17621189
申请日：2020-06-26
Applicant: AMGEN INC.
Inventor： Irwin CHEN , Su CHONG , Fernando GARCES , Mark Leo MICHAELS , Christopher MOHR , Kenneth William WALKER , Zhulun WANG , Neeraj Jagdish AGRAWAL , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Derek E. PIPER , Cen XU
Abstract: The present invention relates to antagonist antibodies of the human calcitonin gene-related peptide (CGRP) receptor as well as bispecific antigen binding proteins derived from the anti-CGRP antibodies that bind to and inhibit both the human CGRP receptor and another target, such as the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) receptor. Pharmaceutical compositions comprising the anti-CGRP receptor antibodies and bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the anti-CGRP receptor antibodies and bispecific antigen binding proteins to ameliorate, treat, or prevent conditions associated with the CGRP and PAC1 receptors, such as chronic pain, migraine, and cluster headache, are also described.
-
公开(公告)号：US20220195022A1
公开(公告)日：2022-06-23
申请号：US17558032
申请日：2021-12-21
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US20180362645A1
公开(公告)日：2018-12-20
申请号：US16017891
申请日：2018-06-25
Applicant: AMGEN INC.
Inventor： Cen XU , Agnes Eva HAMBURGER
IPC: C07K16/28
CPC classification number: C07K16/28 , A61P25/06 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
-
公开(公告)号：US20170247451A1
公开(公告)日：2017-08-31
申请号：US15592115
申请日：2017-05-10
Applicant: AMGEN INC.
Inventor： Cen XU , Agnes Eva HAMBURGER
IPC: A61K47/48 , C07K16/28 , C07K19/00 , A61K39/395
CPC classification number: C07K16/28 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.
-
-
-
-
-
-
-
Search Results
18
records
(took 0.025 seconds)
